IBRX 2.54 ▲ 1.60% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    ImmunityBio Inc.

    NASDAQ: IBRX · Real-Time Price · USD
    2.54
    0.04 (1.60%)
    At close: Oct 03, 2025, 3:59 PM
    2.55
    0.39%
    After-hours: Oct 03, 2025, 07:50 PM EDT
    1.60%
    Bid 2.15
    Market Cap 2.4B
    Revenue (ttm) 56.6M
    Net Income (ttm) -367.09M
    EPS (ttm) -0.48
    PE Ratio (ttm) -5.29
    Forward PE -6.94
    Analyst Buy
    Dividends n/a
    Ask 3.21
    Volume 14,808,895
    Avg. Volume (20D) 9,042,520
    Open 2.54
    Previous Close 2.50
    Day's Range 2.48 - 2.75
    52-Week Range 1.83 - 7.48
    Beta -0.06
    Ex-Dividend Date n/a

    About IBRX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IBRX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    ImmunityBio Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +5.78%
    ImmunityBio shares are trading higher after the co... Unlock content with Pro Subscription
    1 month ago
    -0.88%
    IBRX stock has given up its prior gain. ImmunityBio shares were trading higher after the company announced it has opened a new Phase 2 study to assess the BioShield platform.
    news image

    2 days ago · seekingalpha.com

    ImmunityBio: A Small Bet Is Warranted

    ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up...

    news image

    2 weeks ago · marketbeat.com

    Biotech Breakouts: 3 Stocks With Massive Upside Potential

    Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves i...

    news image

    3 weeks ago · seekingalpha.com

    ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

    I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of f...

    news image

    3 weeks ago · businesswire.com

    ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the Phase 2 QUILT-3.055 study, demonstratin...

    news image

    1 month ago · businesswire.com

    Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with...

    news image

    1 month ago · businesswire.com

    ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored ...

    news image

    1 month ago · businesswire.com

    ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete re...

    news image

    1 month ago · businesswire.com

    ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Ho...

    news image

    2 months ago · fool.com

    IBRX Sales Soar 2,540%

    ImmunityBio (IBRX -0.21%), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating a...

    news image

    2 months ago · zacks.com

    ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

    ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.

    Add to Watchlist